Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study
The following abstract is written by Ali Akbar Hajiaghamohammadi 1, Amir Ziaee, Sonia Oveisi, Homa Masroor References: PMID: 23087748 PMCID: PMC3475019 DOI: 10.5812/hepatmon.6099 Abstract Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons of enzyme increase in liver. In About 10 percent of patients with NAFLD, the disease progresses toward Non Alcoholic Steatohepatitis (NASH) and about one […]